DEERFIELD, Illinois – (COMMERCIAL THREAD) – Baxter International Inc. (NYSE: BAX), a global innovator in kidney care, today announced new data showing that patients with kidney failure could experience an almost double survival rate high and prolonged time to an adverse event (AE) and hospitalization when the Share source The Remote Patient Management Digital Health Platform is used to help manage Automated Peritoneal Dialysis (APD) at home.1
The new data was presented at the American Society of Nephrology’s annual Kidney Week, Nov. 4-7, in an abstracts session, “Remote monitoring of patients with APD may improve clinical outcomes: competing risk regression model analysis, ” [PO0965]. The randomized controlled trial of 815 kidney patients covering 22 hospitals in Mexico evaluated mortality and the first AE or first hospitalization for kidney patients on APD at home with and without the help of digital health management away from patients.
âThe study indicates Sharesource’s role in supporting clinically meaningful outcomes that help kidney patients access home dialysis and stay on treatment for as long as possible, âsaid Peter Rutherford, MB BS, PhD., vice president of medical affairs, Baxter Renal Care. âAs we navigate the COVID-19 pandemic, digital health is demonstrating how it can help healthcare professionals improve clinical outcomes and enable patients to stay home with reduced unplanned hospital visits. ”
Share source Remote patient management allows healthcare professionals to monitor their patients’ home dialysis treatments and then adjust treatment remotely without patients having to visit the clinic unexpectedly. Share source is the most widely implemented home dialysis digital health platform. It is used to care for nearly 50% of all patients on Baxter APD systems worldwide. The digital health platform is available in over 70 countries and has managed over 32 million treatments to date.
Support the wide global adoption of Share source is proof that remote patient management can help healthcare providers quickly detect and respond to catheter issues,2,3,4,5 peritonitis,6 and complications related to compliance,7.8.9 which can lead to a reduction in hospitalizations.ten
The new study was conducted in hospitals that served more than 100 prevalent patients and more than 50 new patients per year and had more than 5 years of experience in APD. Twenty-two hospitals were randomly assigned to perform either remote patient management with APD or conventional APD with equivalent APD equipment. The study followed a total of 815 patients, 417 using remote patient management and 398 on conventional APD, for at least one year.
Patients using only conventional APD in the study had significantly higher all-cause mortality (sHR 1.79, 95% CI (1.15-2.81); p = 0.01), MCV (sHR 2.21, 95% CI (1.07-4.58); p = 0.03) and AE (sHR 1.74, 95% (1.34-2.25); p = 0.001 ) compared to patients using PDA with remote patient management. Data indicates that using remote patient management may improve survival and extend time to first AE and hospitalization compared to those using ODA alone, suggesting that digital health may improve outcomes. clinical outcomes of patients with ODA.
About peritoneal dialysis
People with end-stage kidney disease need dialysis treatment or a kidney transplant to stay alive. PD therapy is usually managed by patients in their homes at a convenient time of the day. It works by cleansing the blood of toxins and removing excess fluid through the peritoneal cavity of the body. Studies show that patients and doctors often prefer home dialysis.11 Parkinson’s patients have improved early survival, higher satisfaction rates, and higher quality of life measures.12.13.14
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, nephrology, hospital and surgical products. For 90 years, we’ve operated at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make them happen. With products, technologies and therapies available in more than 100 countries, Baxter employees around the world are now building on the company’s rich heritage of medical breakthroughs to advance the next generation of innovation. transformers in health care. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
Rx only. For safe and proper use of this device, refer to the complete user manual.
This press release includes forward-looking statements regarding the Share source remote patient management platform, including the potential benefits associated with its use. Statements are based on assumptions about many important factors, including the following, that could cause actual results to differ materially from those of forward-looking statements: market demand and acceptance for new and existing products; risks associated with product development; the inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics / pandemics, regulatory or other); meeting regulatory and other requirements; actions of regulators and other government authorities; product quality, manufacturing or supply or patient safety issues; changes in law and regulations; and other risks identified in Baxter’s latest filing on Form 10-K and other SEC filings, all available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.
Baxter and Share source are registered trademarks of Baxter International Inc.
1 Paniagua R, et al. Summary presented at ASN Kidney Week 2021. Virtual. 2021. [PO0965]
2 JimÃ©nez S & Condia J. Abstract presented at the 17th ISPD Congress. Vancouver, Canada). 2018. [P-337]
3 Garcia I, et al. Summary presented at the 13th Euro-PD Congress. Dublin, Ireland). 2017. [P-63]
4 Jotterand Drepper V, et al. Abstract presented at the ASN Kidney Week congress. Chicago (United States). 2016. [SA-PO023]
5 Rojas-Diaz M, et al. Abstract presented at the ASN Kidney Week congress. New Orleans (United States). 2017. [PUB344]
6 Gomez R, et al. Summary presented at the 13th Euro-PD Congress. Dublin, Ireland). 2017. [P-222]
7 JimÃ©nez S & Condia J. Abstract presented at the 17th ISPD Congress. Vancouver, Canada). 2018. [P-229]
8 Firanek C, et al. Abstract presented at the 54th ERA-EDTA congress. Madrid, Spain). 2017. [MP557]
9 Jotterand Drepper V, et al. Perit Dial Int. 2018; 38: 76-78; 10. Rojas-Diaz M & Ramos A. Abstract presented at ASN Kidney Week congress. New Orleans (United States). 2017. [TH-PO859]
ten Rivera A, et al. Abstract presented at the ASN Kidney Week congress. San Diego (United States). 2018. [FR-PO683]
11 Rivara MB, Mehrotra R. The Changing Landscape of Home Dialysis in the United States. Current Opinion in Nephrology and Hypertension. 2014; 23 (6): 586-591.doi: 10.1097 / MNH00000000000000066; Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar results with hemodialysis and peritoneal dialysis in patients with end stage renal disease. Archives of Internal Medicine. 2011; 171 (2): 110-118. Doi: 10.1001 / archiinternmed.2010.352; Ledebo I, Ronco C. The best dialysis therapy? Results of an international survey of nephrology professionals. Nephrology Dialysis Transplantation. 2008; 6: 403-408.doi: 10.1093 / ndtplus / sfn148; Schiller B, Neitzer A, Doss S. Perceptions of renal replacement therapy among nephrology professionals. News and problems of nephrology. September 2010; 36-44; Ghaffarri A, Kalantar-Zadeh K, Lee J, Maddux F, Moran J, Nissenson A. PD First: Peritoneal dialysis as the default transition to dialysis. Dialysis seminars. 2013; 26 (6): 706-713. doi: 10.1111 / sdi.12125.
12 Rubin HR et al. Patient reviews of dialysis care with peritoneal dialysis vs hemodialysis. JAMA. 2004 Feb 11; 291 (6): 697-703.
13 Juergensen, et al. Hemodialysis and peritoneal dialysis: how patients rate their satisfaction with therapy and the impact of therapy on their lives. Clin J Am Soc Nephrol. 2006; 1 (6): 1191-1196.
14 Zazzeroni LHR et al. Comparison of the quality of life of patients on hemodialysis and peritoneal dialysis: systematic review and meta-analysis. Res. 2017; 42 (4): 717-727. USRDS ADR 2018: ESRD Vol 2, Chap 5; Figure 5.1.